GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00000753 | Oral cavity | OSCC | cell cycle checkpoint | 101/7305 | 169/18723 | 3.53e-08 | 6.68e-07 | 101 |
GO:00427707 | Oral cavity | OSCC | signal transduction in response to DNA damage | 102/7305 | 172/18723 | 5.27e-08 | 9.68e-07 | 102 |
GO:006145817 | Oral cavity | OSCC | reproductive system development | 217/7305 | 427/18723 | 3.75e-07 | 5.63e-06 | 217 |
GO:19019882 | Oral cavity | OSCC | negative regulation of cell cycle phase transition | 136/7305 | 249/18723 | 3.81e-07 | 5.70e-06 | 136 |
GO:004860816 | Oral cavity | OSCC | reproductive structure development | 214/7305 | 424/18723 | 8.58e-07 | 1.18e-05 | 214 |
GO:00018243 | Oral cavity | OSCC | blastocyst development | 66/7305 | 106/18723 | 1.04e-06 | 1.40e-05 | 66 |
GO:00109483 | Oral cavity | OSCC | negative regulation of cell cycle process | 155/7305 | 294/18723 | 1.11e-06 | 1.48e-05 | 155 |
GO:00311226 | Oral cavity | OSCC | cytoplasmic microtubule organization | 39/7305 | 56/18723 | 3.29e-06 | 3.93e-05 | 39 |
GO:00063023 | Oral cavity | OSCC | double-strand break repair | 132/7305 | 251/18723 | 7.93e-06 | 8.52e-05 | 132 |
GO:00315704 | Oral cavity | OSCC | DNA integrity checkpoint | 72/7305 | 123/18723 | 8.77e-06 | 9.31e-05 | 72 |
GO:00335233 | Oral cavity | OSCC | histone H2B ubiquitination | 12/7305 | 12/18723 | 1.24e-05 | 1.26e-04 | 12 |
GO:00000774 | Oral cavity | OSCC | DNA damage checkpoint | 67/7305 | 115/18723 | 2.20e-05 | 2.08e-04 | 67 |
GO:005067310 | Oral cavity | OSCC | epithelial cell proliferation | 212/7305 | 437/18723 | 2.82e-05 | 2.61e-04 | 212 |
GO:00063563 | Oral cavity | OSCC | regulation of transcription by RNA polymerase I | 25/7305 | 34/18723 | 4.63e-05 | 3.90e-04 | 25 |
GO:00018252 | Oral cavity | OSCC | blastocyst formation | 27/7305 | 38/18723 | 6.23e-05 | 5.08e-04 | 27 |
GO:00063601 | Oral cavity | OSCC | transcription by RNA polymerase I | 36/7305 | 55/18723 | 6.42e-05 | 5.22e-04 | 36 |
GO:00459431 | Oral cavity | OSCC | positive regulation of transcription by RNA polymerase I | 18/7305 | 23/18723 | 1.47e-04 | 1.04e-03 | 18 |
GO:00331823 | Oral cavity | OSCC | regulation of histone ubiquitination | 11/7305 | 12/18723 | 2.45e-04 | 1.57e-03 | 11 |
GO:00301983 | Oral cavity | OSCC | extracellular matrix organization | 146/7305 | 301/18723 | 4.67e-04 | 2.77e-03 | 146 |
GO:00452293 | Oral cavity | OSCC | external encapsulating structure organization | 147/7305 | 304/18723 | 5.30e-04 | 3.08e-03 | 147 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
WDR7 | SNV | Missense_Mutation | | c.2250N>G | p.Ile750Met | p.I750M | Q9Y4E6 | protein_coding | tolerated(0.19) | benign(0.015) | TCGA-A1-A0SH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | tc | SD |
WDR7 | SNV | Missense_Mutation | | c.2882C>G | p.Ala961Gly | p.A961G | Q9Y4E6 | protein_coding | tolerated(0.06) | benign(0.017) | TCGA-A1-A0SO-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | | SD |
WDR7 | SNV | Missense_Mutation | rs778537690 | c.1597N>G | p.Ile533Val | p.I533V | Q9Y4E6 | protein_coding | tolerated(0.52) | benign(0) | TCGA-A2-A0EQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
WDR7 | SNV | Missense_Mutation | | c.686N>T | p.Ser229Leu | p.S229L | Q9Y4E6 | protein_coding | deleterious(0.04) | benign(0.023) | TCGA-A7-A26H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | PD |
WDR7 | SNV | Missense_Mutation | | c.3245G>C | p.Gly1082Ala | p.G1082A | Q9Y4E6 | protein_coding | tolerated(0.32) | benign(0.024) | TCGA-A8-A07B-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
WDR7 | SNV | Missense_Mutation | novel | c.1208G>T | p.Ser403Ile | p.S403I | Q9Y4E6 | protein_coding | tolerated(0.16) | benign(0) | TCGA-AR-A24U-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
WDR7 | SNV | Missense_Mutation | | c.1616A>T | p.Asp539Val | p.D539V | Q9Y4E6 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-B6-A0RH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
WDR7 | SNV | Missense_Mutation | | c.1195G>T | p.Val399Leu | p.V399L | Q9Y4E6 | protein_coding | tolerated(0.78) | benign(0) | TCGA-BH-A18T-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
WDR7 | SNV | Missense_Mutation | novel | c.2219N>T | p.Ala740Val | p.A740V | Q9Y4E6 | protein_coding | tolerated(0.13) | benign(0.021) | TCGA-C8-A8HR-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | CR |
WDR7 | SNV | Missense_Mutation | | c.1991G>C | p.Gly664Ala | p.G664A | Q9Y4E6 | protein_coding | tolerated(0.12) | possibly_damaging(0.775) | TCGA-EW-A1OV-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | epirubicin | SD |